Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3333818 | Seminars in Hematology | 2008 | 10 Pages |
Abstract
Patients with myelodysplastic syndrome (MDS) have intrinsic, usually acquired genetic defects in their hematopoietic stem cells, but some others exhibit T-cell-mediated inhibition of hematopoiesis and good responses to immunosuppression. In these cases, MDS shares a similar pathophysiology with aplastic anemia (AA). Here, we review the evidence supporting a role of the immune system in the pathophysiology of MDS and the results of clinical trials of immunosuppressive agents.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Elaine M. Sloand, Katayoun Rezvani,